Robert C Doebele
Overview
Explore the profile of Robert C Doebele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
11696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez-Martinez D, Roth L, Mumford T, Guan J, Le A, Doebele R, et al.
Nat Commun
. 2024 Nov;
15(1):9473.
PMID: 39488530
Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of interactions between oncogene...
2.
Concannon K, Glisson B, Doebele R, Huang C, Marotti M, Camidge D, et al.
Clin Lung Cancer
. 2024 Sep;
25(7):601-611.
PMID: 39307607
Introduction: Small cell lung cancer (SCLC) is known to express high levels of the proangiogenic factor vascular endothelial growth factor (VEGF). We assessed the safety and tolerability of cediranib, an...
3.
Hu Q, Remsing Rix L, Desai B, Miroshnychenko D, Li X, Welsh E, et al.
bioRxiv
. 2024 Sep;
PMID: 39253447
Cancer-associated fibroblasts (CAFs) are associated with tumor progression and modulate drug sensitivity of cancer cells. However, the underlying mechanisms are often incompletely understood and crosstalk between tumor cells and CAFs...
4.
Robichaux J, Elamin Y, Tan Z, Carter B, Zhang S, Liu S, et al.
Nat Med
. 2024 Aug;
30(9):2694-2695.
PMID: 39164519
No abstract available.
5.
Blakely C, Urisman A, Gubens M, Mulvey C, Allen G, Shiboski S, et al.
J Clin Oncol
. 2024 Jul;
42(26):3105-3114.
PMID: 39028931
Purpose: To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA -mutated...
6.
Liao Y, Remsing Rix L, Li X, Fang B, Izumi V, Welsh E, et al.
Cell Chem Biol
. 2023 Oct;
31(2):284-297.e10.
PMID: 37848034
Multiple tyrosine kinase inhibitors (TKIs) are often developed for the same indication. However, their relative overall efficacy is frequently incompletely understood and they may harbor unrecognized targets that cooperate with...
7.
Chen N, Tyler L, Le A, Welsh E, Fang B, Elliott A, et al.
Mol Cancer Ther
. 2023 Sep;
23(1):92-105.
PMID: 37748191
Despite the initial benefit from tyrosine kinase inhibitors (TKI) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare and resistance ultimately emerges from...
8.
Peters T, Chen N, Tyler L, Le A, Dimou A, Doebele R
Thorac Cancer
. 2023 Sep;
14(33):3259-3265.
PMID: 37727007
Background: The vast majority of patients with ROS1 positive non-small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion...
9.
Schubert L, Le A, Hinz T, Navarro A, Nelson-Taylor S, Nemenoff R, et al.
Biol Open
. 2023 Jul;
12(8).
PMID: 37470475
CRISPR/Cas9 gene editing represents a powerful tool for investigating fusion oncogenes in cancer biology. Successful experiments require that sgRNAs correctly associate with their target sequence and initiate double stranded breaks...
10.
Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield S, et al.
J Thorac Oncol
. 2023 May;
18(9):1165-1183.
PMID: 37182602
Introduction: Although targeted therapies have revolutionized the therapeutic landscape of lung adenocarcinomas (LUADs), disease progression on single-agent targeted therapy against known oncogenic drivers is common, and therapeutic options after disease...